Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (153)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Immune Globulin IV (Onc/Hematology Use)	Hematinic / Clotting Factor / Plasma Product	Hematologic
Molecule Immune Globulin IV (Onc/Hematology Use) Therapeutic Category Supportive Care (Hematinic / Coagulation Factor) Oncology Type Hematologic Drug Class / Mechanism Hematinic / Clotting Factor / Plasma Product
Magrolimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Magrolimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Evorpacept	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Evorpacept Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Lemzoparlimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Lemzoparlimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Letaplimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
IBI322 (CD47/PD-L1)	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule IBI322 (CD47/PD-L1) Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
TTI-621 (Cibisatamab-related)	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule TTI-621 (Cibisatamab-related) Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Cibisatamab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Cibisatamab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Ianalumab	Targeted Protein Degrader	Hematologic
Molecule Ianalumab Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
CFT7455 (Cereblon Degrader)	Targeted Protein Degrader	Hematologic
Molecule CFT7455 (Cereblon Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
BGB-16673 (BTK Degrader)	Targeted Protein Degrader	Hematologic
Molecule BGB-16673 (BTK Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
NX-2127 (BTK Degrader)	Targeted Protein Degrader	Hematologic
Molecule NX-2127 (BTK Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader

Immune Globulin IV (Onc/Hematology Use) Supportive Care (Hematinic / Coagulation Factor)
Therapeutic Category Supportive Care (Hematinic / Coagulation Factor) Oncology Type Hematologic Drug Class / Mechanism Hematinic / Clotting Factor / Plasma Product
Magrolimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Evorpacept Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Lemzoparlimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
IBI322 (CD47/PD-L1) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
TTI-621 (Cibisatamab-related) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Cibisatamab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Ianalumab Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
CFT7455 (Cereblon Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
BGB-16673 (BTK Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
NX-2127 (BTK Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader

‹ 1 … 10 11 12 13 ›

Product Range

Company

Global Network

Products

Immune Globulin IV (Onc/Hematology Use)

Magrolimab

Evorpacept

Lemzoparlimab

Letaplimab

IBI322 (CD47/PD-L1)

TTI-621 (Cibisatamab-related)

Cibisatamab

Ianalumab

CFT7455 (Cereblon Degrader)

BGB-16673 (BTK Degrader)

NX-2127 (BTK Degrader)

Immune Globulin IV (Onc/Hematology Use)

Magrolimab

Evorpacept

Lemzoparlimab

Letaplimab

IBI322 (CD47/PD-L1)

TTI-621 (Cibisatamab-related)

Cibisatamab

Ianalumab

CFT7455 (Cereblon Degrader)

BGB-16673 (BTK Degrader)

NX-2127 (BTK Degrader)